Are neurotrophins important in ulcerative colitis?

Annals of the New York Academy of Sciences

Volumn 1107, Issue , 2007, Pages 290-299

  Johansson, Malin ^a   Norrg̊ard, Örjan ^a   Forsgren, Sture ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Colitis; Inflammation; Neurotrophin receptors; Neurotrophins; TNF

Indexed keywords

CYTOKINE; INFLIXIMAB; INTERLEUKIN 6; NEUROTROPHIN; NEUROTROPHIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR;

CONFERENCE PAPER; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE SEVERITY; DOWN REGULATION; ENTERITIS; HEALING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LAMINA PROPRIA; NONHUMAN; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS; UPREGULATION; ANIMAL; ARTICLE; METABOLISM; PATHOLOGY;

ANIMALS; COLITIS, ULCERATIVE; CYTOKINES; HUMANS; NERVE GROWTH FACTORS; RECEPTOR, NERVE GROWTH FACTOR;

EID: 34648832274     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1381.031     Document Type: Conference Paper

References (58)

1. KORSCHING, S.1993. The neurotrophic factor concept: a reexamination. J. Neuroscience. 13: 2739-2748.
2. THORNE, R.G. & W.H. FREY. 2001. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin. Pharmacokinet. 40: 907-946.
3. MARTIN-ZANCA, D. et al. 1989. Molecular and biochemical characterization of the human trk proto-oncogene. Mol. Cell Biol. 9: 24-33.
4. CHAPMAN, B.S. & I.D. KUNTZ. 1995. Modelled structure of the 75-kDa neurotrophin receptor. Protein Sci. 4: 1696-1707.
5. NOCKHER, W.A. & H. RENZ. 2005. Neurotrophins in clinical diagnosis: pathophysiology and laboratory investigation. Clinica Chimica Acta 352: 49-74.
6. DOLLE, L. et al. 2004. Nerve growth factor receptors and signalling in breast cancer. Curr. Cancer Drug Targets. 4: 463-470.
7. DAWBARN, D. & S.J. ALLEN. 2003. Neurotrophins and neurodegeneration. Neuropathol. Appl. Neurobiol. 29: 211-230.
8. PHILLIPS, H.S. et al. 1991. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7: 695-702.
9. CONNOR, B. et al. 1997. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res. Mol. Brain Res. 49: 71-81.
10. MARTIN-ZANCA, D. et al. 1986. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 5: 743-748.
11. BONGARZONE, I. et al. 1989. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 4: 1457-1462.
12. HALLIDAY, D.A. et al. 1998. Elevated nerve growth factor levels in the synovial fluid of patients with inflammatory joint disease. Neurochem Res. 23: 919-922.
13. GILLARDON, F. et al. 1995. Increase in neuronal Jun immunoreactivity and epidermal NGF levels following UV exposure of rat skin. Neuroreport. 6: 1322-1324.
14. GEE, A.P. et al. 1983. Nerve growth factor: stimulation of polymorphnuclear leukocyte chemotaxis. Proc. Natl. Acad. Sci. USA 80: 7215-7218.
15. FRIESS, H. et al. 1999. Nerve growth factor and its high-affinity receptor in chronic pancreatitis. Ann. Surg. 230: 615-624.
16. MANNI, L. et al. 2003. Nerve growth factor release by human synovial fibroblasts prior to and following exposure to tumor necrosis factor-alpha, interleukin-1 beta and cholecystokinin-8: the possible role of NGF in the inflammatory response. Clin. Exp. Rheumatol. 21: 617-624.
17. MANNI, L. et al. 2002. Role of cholecystokinin-8 in nerve growth factor and nerve growth factor mRNA expression in carragenaan-induced joint inflammation in adult rats. Rheumatology 41: 787-792.
18. MUANGMAN, P. et al. 2004. Nerve growth factor accelerates wound healing in diabetic rats. Wound Repair Regen. 12: 44-52.
19. BOWLES, W.R. et al. 2004. Nerve growth factor treatment enhances release of immunoreactive calcitonin gene-related peptide but not substance P from dorsal horn slices in rats. Neurosci. Lett. 363: 239-242.
20. LINNARSSON, S. et al. 2000. Cell death in regenerating populations of neurons in BDNF mutant mice. Mol. Brain Res. 75: 61-69.
21. LEVI-MONTALCINI, R. et al. 1990. A role for nerve growth factor in nervous, endocrine and immune systems. Prog. Neuroendocrinimmunol. 3: 1-10.
22. KERSCHENSTEINER, M. et al. 1999. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J. Exp. Med. 189: 865-870.
23. REINSHAGEN, M. et al. 2000. Protective role of neurotrophins in experimental inflammation of the rat gut. Gastroenterology 119: 368-376.
24. BENNETT, D. 2001. Neurotrophic factors: important regulators of nociceptive function. Neuroscientist 7: 13-17.
25. LAMB, K. et al. 2004. Increased nerve growth factor expression triggers bladder overactivity. J. Pain. 5: 150-156.
26. WOOLF, C.J. et al. 1994. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 62: 327-331.
27. GARRAWAY, S.M. et al. 2003. BDNF sensitizes the response of lamina II neurons to high threshold primary afferent inputs. Eur. J. Neurosci. 18: 2467-2476.
28. PATAPOUTIAN, A. & L. REICHARDT. 2001. Trk receptors: mediators of neurotrophin action. Curr. Opinion Neurobiol. 11: 272-280.
29. TORTOROLO, L. et al. 2005. Neurotrophin overexpression in lower airways of infants with respiratory syncytial virus infection. Am. J. Respir. Crit. Care Med. 172: 233-237.
30. HOEHNER, J.C. et al. 2006. Localization of neurotrophins and their high-affinity receptors during human enteric nervous system development. Gastroenterology 110: 756-767.
31. DI MOLA, F.F. et al. 2000. Nerve growth factor and Trk high affinity receptor (TrkA) gene expression in inflammatory bowel disease. Gut 46: 670-679.
32. LEE, C.M. et al. 2002. Neuropeptides and nerve growth in inflammatory bowel diseases: a quantitative immunohistochemical study. Dig. Dis. Sci. 47: 495-502.
33. SKAPER, S.D. et al. 2001. Mast cells differentially express and release active high molecular weight neurotrophins. Brain Res. Mol. Brain Res. 97: 177-185.
34. JOHANSSON, M. et al. 2007. Study of expression patterns and levels of neurotrophins and neurotrophin receptors in ulcerative colitis. Inflamm. Bowel Dis. 13: In press.
35. KANNAN, Y. et al. 1996. Nerve growth factor and cytokines mediate lymphoid tissue-induced neurite outgrowth from mouse superior cervical ganglia in vitro. J. Immunol.157: 313-320.
36. SAFIEH-GARABEDIAN, B. et al. 1995. Contribution of IL-1 beta to the inflammation-induced increase in NGF levels and inflammatory hyperalgesia. Br. J. Pharmacol. 115: 1265-1275.
37. WANG, B. et al. 2005. Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-alpha. Am. J. Physiol. Endocrinol. Metab. 288: 731-740.
38. SCHULTE-HERBRUGGEN, O. et al. 2005. Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J. Neuroimmunol. 160: 204-209.
39. ALOE, L. et al. 1995. Effect of NGF antibodies on mast cell distribution, histamine substance P levels in the knee joint of TNF-arthritic transgen mice. Rheumatol. Int. 14: 249-252.
40. MARSHALL, J.S. et al. 1999. Nerve growth factor modifies the expression of inflammatory cytokines by mast cells via a prostanoid-dependent mechanism. J. Immunol. 162: 4271-4276.
41. GONZALEZ, R.R. et al. 2005. Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis. J. Urol. 173: 630-634.
42. BABYATSKY, M. et al. 1996. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 110: 975-984.
43. DELAFOY, L. et al. 2003. Role of nerve growth factor in the trinitrobenzene sulfonic acid-induced colonic hypersensitivity. Pain 105: 489-497.
44. TORRENTS, D. et al. 2002. Antinerve growth factor treatment prevents intestinal dysmotility in Trichinella spiralis-infected rats. Pharmacol. Exp. Ther. 302: 659-665.
45. COULIE, B. et al. 2000. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 119: 41-50.
46. MA, D. et al. 2003. Interleukin-10 and nerve growth factor have reciprocal upregulatory effects on intestinal epithelial cells. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284: 1323-1329.
47. ALOE, L. 2004. Nerve growth factor, human skin ulcers and vascularization. Our experience. Prog. Brain Res. 146: 515-522.
48. CELLINI, M. et al. 2006. The use of nerve growth factor in surgical wound healing of the cornea. Ophthalmic Res. 38: 177-181.
49. SHI, C.M. et al. 2003. Effects of the nerve growth factor on the survival and wound healing in mice with combined radiation and wound healing. J. Radiat. Res. (Tokyo). 44: 223-228.
50. LIN, A. et al. 2005. Selective loss of NGF-sensitive neurons following experimental colitis. Exp. Neurol. 191: 337-343.
51. GEBOES, K. & S. COLLINS. 1998. Structural abnormalities of the nervous system in Crohn's disease and ulcerative colitis. Neurogastroenterol. Motil. 10: 189-202.
52. BAERT, F. et al. 2004. Management of ulcerative colitis and Crohn's disease. Acta Clin. Belg. 59: 304-314.
53. KOHN, A. et al. 2004. Infliximab in the treatment of severe ulcerative colitis: a follow-up study. Eur. Rev. Med. Pharmacol. Sci. 8: 235-237.
54. RUTGEERTS, P. et al. 2005. Infliximab for induction and maintenance therapy for ulcerative colitis. New Engl. J. Med. 353: 2462-2476.
55. JÄRNEROT, G. et al. 2005. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128: 1805-1811.
56. SANDBORN, W.J. 2004. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease. Rev. Gastroenterol. Disord. 3: 25-33.
57. BAIDOO, L. & G.R. LICHTENSTEIN. 2005. What next after infliximab? Am. J. Gastroenterol. 100: 80-83.
58. OTTAWAY, C.A. 1996. Role of the neuroendocrine system in cytokine pathways in inflammatory bowel disease. Aliment Pharmacol. Ther. 2: 10-15.